-
公开(公告)号：KR1020130126554A
公开(公告)日：2013-11-20
申请号：KR1020130053814
申请日：2013-05-13
Applicant: 가톨릭대학교 산학협력단
IPC: G01N33/53 , G01N33/563 , C12Q1/02
CPC classification number: G01N33/5091 , G01N33/56966 , G01N33/56972 , G01N33/56977 , G01N33/6866 , G01N33/6869 , G01N2333/57 , G01N2800/245
Abstract: The present invention relates to a monitoring kit for an immune status after transplantation, and more particularly, a monitoring kit for the immune status after the transplantation, containing materials for measuring Th17 cells, Treg cells, Th1 cells, CD8EM(CD8 effect memory) IFN-γ-positive cells, and CD8CM(CD8 central memory) IFN-γ-positive cells, and a monitoring method for the immune status of the individual receiving the transplantation including a step of measuring the cell number of Th17 cells, Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the peripheral blood of an object receiving the transplantation, and a step for calculating each cell number ratio of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the number of Th17 cells by dividing the measured values of cell numbers of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells with the measured value of the cell number of Th17 cells. The monitoring method and kit for the immune status of the individual receiving the transplantation provided by the present invention are capable of determining the immune status with ease and accuracy, thereby reducing the excessive use of an immunosuppressant prescribed after transplantation and managing the immune status of each patient. [Reference numerals] (AA,EE,II,MM,QQ,UU) Normally take CNI (100% taking);(BB,DD,FF,HH,JJ,LL,NN,PP,RR,TT,VV,XX) Reduce CNI by 25% (75% taking);(CC,GG,KK,OO,SS,WW) Reduce CNI 50% (50% taking)
Abstract translation: 本发明涉及用于移植后免疫状态的监测试剂盒，更具体地，涉及用于移植后免疫状态的监测试剂盒，其包含用于测量Th17细胞，Treg细胞，Th1细胞，CD8EM（CD8效应记忆）IFN - γ阳性细胞和CD8CM（CD8中枢记忆）IFN-γ阳性细胞，以及接受移植的个体的免疫状态的监测方法，包括测量Th17细胞，Treg细胞的细胞数的步骤 ，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞对抗接受移植的对象的外周血，以及计算Treg细胞，Th1细胞，CD8EM的每个细胞数比例的步骤 通过将Treg细胞，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN的细胞数量的测量值除以相对于Th17细胞数量的IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞 - ＆伽马; -posi T细胞与Th17细胞的细胞数量的测量值。 本发明提供的接受移植的个体的免疫状态的监测方法和试剂盒能够容易且准确地测定免疫状态，从而减少移植后规定的免疫抑制剂的过度使用，并且管理每种免疫抑制剂的免疫状态 患者。 （AA，EE，II，MM，QQ，UU）通常采用CNI（100％服用）;（BB，DD，FF，HH，JJ，LL，NN，PP，RR，TT，VV，XX ）将CNI降低25％（75％服用）;（CC，GG，KK，OO，SS，WW）减少CNI 50％（50％服用）
-
公开(公告)号：KR1020130122555A
公开(公告)日：2013-11-07
申请号：KR1020130045995
申请日：2013-04-25
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/12 , C12N5/0783 , A61P37/00
Abstract: The present invention relates to novel uses of curcumin which inhibits differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition for suppressing differentiation of regulatory T cells (Treg) including curcumin as an active ingredient into etiology cells; a composition for preventing or treating autoimmune diseases including curcumin and regulatory T cells (Treg) as active ingredients; a method of manufacturing regulatory T cells (Treg) which maintains immune suppressing function using curcumin; and a method for suppressing conversion of regulatory T cells (Treg) into etiology cells by using curcumin. The curcumin according to the present invention has a novel use which effectively maintains and reinforces the functions of regulatory T cells (Treg) by suppressing differentiation plasticity of the regulatory T cells into etiology cells so that the curcumin can block differentiation of regulatory T cells (Treg) into etiology cells and maximize effects of preventing or treating autoimmune diseases when the curcumin is used in parallel with the regulatory T cells (Treg) which are cell therapy products. In addition, the curcumin is a natural substance so that the curcumin can be used for long time without toxicity and side effects and have stable effects on body.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的姜黄素的新用途，具体地，涉及抑制作为活性成分的姜黄素调节性T细胞（Treg）分化为病因细胞的组合物; 用于预防或治疗包括姜黄素和调节性T细胞（Treg）作为活性成分的自身免疫性疾病的组合物; 使用姜黄素维持免疫抑制功能的调节性T细胞（Treg）的制备方法; 以及通过使用姜黄素抑制调节性T细胞（Treg）转化为病因细胞的方法。 根据本发明的姜黄素具有通过抑制调节性T细胞向病因细胞的分化可塑性而有效维持并增强调节性T细胞（Treg）的功能的新用途，使得姜黄素可以阻断调节性T细胞（Treg）的分化 ）进入病因细胞，并且当姜黄素与作为细胞治疗产品的调节性T细胞（Treg）并行使用时，预防或治疗自身免疫性疾病的效果最大化。 此外，姜黄素是天然物质，因此姜黄素可长时间使用，无毒副作用，对身体有较好的疗效。
-
公开(公告)号：KR1020130122446A
公开(公告)日：2013-11-07
申请号：KR1020120045791
申请日：2012-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0783 , C07D307/79 , A61K35/12
CPC classification number: C12N5/0646 , A61K35/12 , C07D307/79 , C12N2502/1114
Abstract: The present invention relates to a novel use of tanshinone IIA which suppresses differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition containing tanshinone IIA as an active ingredient for suppressing differentiation of Treg cell into Th17 cells; a composition containing tanshinone IIA and Treg cells as active ingredients for preventing or treating immune diseases; and a method for producing Treg cells using tanshinone IIA, in which immunosuppressive function is maintained. According to the present invention, tanshinone IIA effectively maintains and enhances the function of Treg cells by suppressing differentiation plasticity of Treg cells into Th17 cells, thereby blocking differentiation of Treg cells into Th17 cells under a pathological condition when being alternately used with Treg cells and providing a therapeutic agent for effectively treating immune diseases.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的新丹西酮IIA的新用途，具体地，涉及含有丹参酮IIA作为抑制Treg细胞分化为Th17细胞的活性成分的组合物的新用途。 含有丹参酮IIA和Treg细胞作为预防或治疗免疫疾病的有效成分的组合物; 以及维持免疫抑制功能的使用丹参酮IIA的Treg细胞的制造方法。 根据本发明，丹参酮IIA通过抑制Treg细胞分化为Th17细胞的可塑性，有效维持和增强Treg细胞的功能，从而在与Treg细胞交替使用时在病理条件下阻断Treg细胞分化为Th17细胞，并提供 用于有效治疗免疫疾病的治疗剂。
-
公开(公告)号：KR101301262B1
公开(公告)日：2013-08-27
申请号：KR1020090101194
申请日：2009-10-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/495 , A61K35/28 , A61K38/00 , C12N5/0663 , C12N2501/15 , C12N2510/00 , A61K2300/00
Abstract: 본 발명의 하나이상의 구체예는 TGFβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도를 제공한다.
간엽줄기세포, 자가면역질환, CD4+CD25+ Foxp3 조절성 T 세포, Th17-
85.发明公开세포투과성을 갖는 Ｒ12 - Ｇｒｉｍ19 융합 펩타이드 및 이를 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물 审中-实审R12-GRIM19具有用于预防或治疗免疫疾病的细胞渗透和包含其的药物组合物的融合肽
公开(公告)号：KR1020130090054A
公开(公告)日：2013-08-13
申请号：KR1020120011092
申请日：2012-02-03
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/4747 , A61K38/1761 , A61K47/64 , C07K7/08 , C07K2319/03
Abstract: PURPOSE: R12-Grim19 fusion peptide is provided to be usefully used as an immune suppressant or a pharmaceutical composition which prevents or treats immune disease including autoimmune disease due to the modulation of an immune reaction, inflammation disease and transplantation rejection disease. CONSTITUTION: Recombinant peptide in which twelve successive arginene (R) and Grim19 are fused is provided. The recombinant peptide has an amino acid sequence represented by a sequence number 1. A vector includes a base sequence coding the peptide. The base sequence comprises a base sequence represented by a sequence number 2. A composition for prevention or treatment of the immune disease includes the peptide.
Abstract translation: 目的：提供R12-Grim19融合肽有效地用作免疫抑制剂或由于免疫反应，炎症疾病和移植排斥疾病的调节而预防或治疗包括自身免疫疾病在内的免疫疾病的药物组合物。 构成：提供其中十二个连续的精氨酸（R）和Grim19融合的重组肽。 重组肽具有由序列号1表示的氨基酸序列。载体包括编码该肽的碱基序列。 碱基序列包含由序列号2表示的碱基序列。用于预防或治疗免疫疾病的组合物包括该肽。
-
Patent Agency Ranking
公开(公告)号：KR1020120129120A
公开(公告)日：2012-11-28
申请号：KR1020110047180
申请日：2011-05-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/203 , A61K9/127 , A61P29/00 , A61P37/00
Abstract: PURPOSE: An immunotherapeutic agent of a nanosome form containing retinoic acid is provided to ensure high retinoic acid transfer rate to a target site and to effectively suppress TNF-alpha and IL-17 generation. CONSTITUTION: An immunotherapeutic agent of a nanosome form contains a cell suspension and retinoic acid. The cell suspension is a cell membrane in eukaryotic cell lysate. The immune diseases are autoimmune diseases, inflammatory diseases, and cell, tissue, or organ transplantation rejection. A method for manufacturing the immunotherapeutic agent comprises: a step of suspending eukaryotic cells; a step of passing the suspension solution through a membrane filter; a step of adding retinoic acid to the solution; and a step of isolating immunotherapeutic agent of a nanosome from the solution. [Reference numerals] (AA) RA-containing nanosome
Abstract translation: 目的：提供含有视黄酸的纳米体形式的免疫治疗剂，以确保目标部位的高视黄酸转移率，有效抑制TNF-α和IL-17的产生。 构成：纳米体形式的免疫治疗剂含有细胞悬浮液和视黄酸。 细胞悬浮液是真核细胞裂解物中的细胞膜。 免疫疾病是自身免疫疾病，炎性疾病，细胞，组织或器官移植排斥。 制备免疫治疗剂的方法包括：使真核细胞悬浮的步骤; 使悬浮液通过膜过滤器的步骤; 向溶液中加入视黄酸的步骤; 以及从溶液中分离纳米体的免疫治疗剂的步骤。 （AA）RA的纳米体
-
公开(公告)号：KR101187195B1
公开(公告)日：2012-10-02
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 위장관 궤양(gastrointestinal ulcer)의 예방 또는 치료용 약학 조성물을 제공한다.-
公开(公告)号：KR1020120095046A
公开(公告)日：2012-08-28
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/20 , A61K48/005 , Y10S424/81
Abstract: PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Abstract translation: 目的：提供一种用于预防或治疗免疫排斥疾病（包括IL-27）的组合物，用于通过在移植的细胞或器官移植后抑制对宿主的排斥来减轻免疫排斥疾病。 构成：用于预防或治疗免疫排斥疾病的组合物包括IL-27作为活性成分。 IL-27具有序列号1（SEQ ID NO：1）中描述的氨基酸序列。 用于预防或治疗免疫排斥疾病的组合物包括编码IL-27作为活性成分的含有多核苷酸的载体。 多核苷酸具有序列号2中描述的碱基序列。免疫排斥疾病是移植物抗宿主病。
-
公开(公告)号：KR101144563B1
公开(公告)日：2012-05-11
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
-
90.发明公开유럽종 포도의 씨 추출물 및 레바미피드를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물 有权用于预防或治疗包含VITIS VINIFERA PIP提取物和雷巴米地的含盐酸盐的药物组合物
公开(公告)号：KR1020120032649A
公开(公告)日：2012-04-06
申请号：KR1020100094091
申请日：2010-09-29
Applicant: 한림제약(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing rebamipide and Vitis vinifera seed extract is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rebamipide and Vitis vinifera seed extract. The pharmaceutical composition is orally administered in the form of a tablet or capsule. The dosage of rebamipide is 0.3 mg/kg a day.
Abstract translation: 目的：提供含有瑞巴派特和葡萄种子提取物的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有瑞巴派特和葡萄籽种子提取物。 药物组合物以片剂或胶囊的形式口服给药。 瑞巴派特的剂量为每天0.3mg / kg。
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.034 seconds)
